At Moderna, our mission is to deliver the greatest possible impact to people through messenger RNA (mRNA) medicines. For more than a decade, we have been pioneering the potential of mRNA to develop therapeutics and vaccines for infectious disease, immuno-oncology, rare diseases, cardiovascular disease and autoimmune diseases. Most notably, these capabilities contributed to the authorization and approval of one of the earliest and most effective COVID-19 vaccines. In Canada, Moderna has a 10-year strategic partnership with the Canadian government to enhance pandemic response capabilities. This includes building an advanced mRNA manufacturing facility to produce respiratory vaccines currently under construction in Quebec.  Moderna is also committed to helping position Canada as a leader in mRNA research and development with partnerships across the country. To learn more, visit www.modernatx.com/en-CA